APDA News Page 7

FDA Approves Focused Ultrasound for Tremor-predominant Parkinsonโ€™s disease

Posted on by Phil Franchina

FDA approves focused ultrasound for tremor-predominant Parkinsonโ€™s disease December 19, 2018 Tremor-predominant Parkinsonโ€™s disease (PD) joins Essential tremor (ET)...see more as an FDA-approved indication for the use of Focused ultrasound. Focused ultrasound is a technology in which beams of ultrasound waves are focused on a designated target thereby concentrating enough energy to create a small lesion. […]

Read More

INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERSยฎ – Parkinson’s Disease Updates

Posted on by Phil Franchina

INTERNATIONAL CONGRESS OF PARKINSON'S DISEASE AND MOVEMENT DISORDERSยฎ - Parkinson's Disease Updates The International Congress of Parkinsonโ€™s Disease and Movement...see more Disorders is taking place this week (Oct 5-9) in Hong Kong. This is an annual meeting of Movement Disorders scientists and physicians from around the world.

Read More

APDA-funded Brigham and Womenโ€™s Hospital explores the genetic variants associated with Parkinsonโ€™s disease and other conditions

Posted on by Phil Franchina

APDA-funded Brigham and Womenโ€™s Hospital explores the genetic variants associated with Parkinsonโ€™s disease and other neuropsychiatric conditions In classic biochemistry,...see more ribonucleic acid (RNA) was thought to be a simple middle man between our genome and our proteins. Recently, however, it has become clear that RNA exists in multiple forms and plays a myriad of roles, including regulating protein production, regulating genome activity, and sensing environment. In fact, only a very small portion of DNA gets transcribed into RNA that creates protein. A much large portion gets transcribed into RNA that has various other functions.

Read More

FDA New Analysis on PD Psychosis Treatment

Posted on by Phil Franchina

On September 20, 2018, the FDA recently released results of a new analysis...see more finding no new or unexpected safety risks associated with Nuplazid. The new analysis was initiated because of concerns raised in the media last spring, and reassures patients that they should continue to take Nuplazid as prescribed by their physician. The FDA report highlights a number of important concepts

Read More